Testing remdesivir for RSV in hospitalized children under 2
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 2 years old and weigh at least 4.4 pounds (2 kg).
- Your child must have had RSV symptoms for less than 1 week and tested positive for RSV.
- Your child must be hospitalized and have at least 2 of these signs: trouble feeding, low oxygen levels, or fast/working breathing.
- Your child cannot have other serious medical conditions that require hospital care (except conditions that raise RSV risk, like heart or lung disease).
- Your child must not have taken other RSV antiviral medicines in the last 24 hours.
- Your child must have normal liver and kidney function for their age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.